tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Trinity Biotech Regains Nasdaq Compliance as of September 2025

Story Highlights
  • Trinity Biotech regained compliance with Nasdaq listing requirements on September 2, 2025.
  • The company resolved its compliance issues, crucial for maintaining its Nasdaq listing.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Trinity Biotech Regains Nasdaq Compliance as of September 2025

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Trinity Biotech ( (TRIB) ) has shared an announcement.

On September 2, 2025, Trinity Biotech announced it regained compliance with Nasdaq’s listing requirements, specifically the $1.00 minimum bid price and the minimum market value of publicly held shares. This follows a period of non-compliance noted on March 14, 2025, and subsequent improvements in share price and market value by August 2025. The resolution of these compliance issues is significant for Trinity Biotech’s continued listing on the Nasdaq, which is crucial for maintaining investor confidence and market presence.

The most recent analyst rating on (TRIB) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Trinity Biotech stock, see the TRIB Stock Forecast page.

Spark’s Take on TRIB Stock

According to Spark, TipRanks’ AI Analyst, TRIB is a Neutral.

Trinity Biotech’s overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues, negative profitability, and high debt levels. While technical analysis shows some positive momentum, the poor valuation metrics further weigh down the score.

To see Spark’s full report on TRIB stock, click here.

More about Trinity Biotech

Trinity Biotech is a commercial-stage biotechnology company specializing in human diagnostics and diabetes management solutions, including wearable biosensors. The company develops, acquires, manufactures, and markets diagnostic systems for point-of-care and clinical laboratory segments, and has recently expanded into the wearable biosensor industry with the acquisition of Waveform Technologies Inc.’s biosensor assets. Trinity Biotech’s products are used to detect infectious diseases and measure Haemoglobin A1c levels, among other chemistry parameters, and are distributed directly in the U.S. and through international partners in over 75 countries.

Average Trading Volume: 5,217,244

Technical Sentiment Signal: Hold

Current Market Cap: $26.36M

For detailed information about TRIB stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1